OncoQuest Announces Signing of a Definitive Agreement to Sell Drug Portfolio to Dual Industrial for U.S. $300 Million and Commitment to Fund the Oregovomab Phase 3 Clinical Trial in Frontline Ovarian Cancer

EDMONTON, Alberta, April 23, 2020 /PRNewswire/ -- OncoQuest Inc., ("OncoQuest" or the "Company") a privately held, cancer immunotherapy company today announced that it has entered into a definitive agreement to sell its clinical and preclinical immunotherapy development assets to Dual Industrial ...